Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 36800 clinical trials
Diffusion Basis Spectrum Imaging of the Prostate

Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.

biopsy of prostate
prostate cancer screening
  • 0 views
  • 16 Feb, 2024
  • 1 location
MRI-guided Focal Laser Ablation

Magnetic resonance imaging-guided focal laser ablation of prostate cancer.

transrectal ultrasound
MRI
laser ablation
diffusion weighted imaging
prostate specific antigen
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.

adenocarcinoma
hbed-cc
stereotactic body radiation therapy
adenocarcinoma of prostate
metastasis
  • 16 views
  • 05 Aug, 2020
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …

metastatic castration-resistant prostate cancer
diphosphonates
bone lesion
metastasis
castration-resistant prostate cancer
  • 0 views
  • 05 Aug, 2020
Lutetium-177-PSMA-I&T in Oligo-metastatic Hormone Sensitive Prostate Cancer

  Radioligand therapy (RLT) using Lutetium-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells.

enzalutamide
taxane
endocrine therapy
adjuvant
platelet count
  • 4 views
  • 22 Aug, 2020
18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer

The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Veterans. In this study, the management plan prior to and after 18F-DCFPyL PET/CT will be recorded by specific questionnaires and corresponding …

positron emission tomography
prostate cancer metastatic
ct scan
pet/ct scan
external beam radiation therapy
  • 0 views
  • 05 Aug, 2020
Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.

enzalutamide
darolutamide
endocrine therapy
orchiectomy
gonadorelin
  • 0 views
  • 05 Aug, 2020
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research participant's blood that have been genetically modified to express a …

biotherapy
steroid therapy
neuroblastoma
mibg
suicide
  • 0 views
  • 16 Feb, 2024
  • 1 location
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …

cancer treatment
ct scan
chronic lymphocytic leukemia
measurable disease
lymphoma
  • 0 views
  • 04 Dec, 2020
  • 5 locations
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and …

neutrophil count
serum bilirubin level
platelet count
measurable disease
liver metastasis
  • 0 views
  • 16 Feb, 2024
  • 1 location